Selexis offers comprehensive and rapid solutions for the development of stable, high-yield, and clonal mammalian cell lines that are used in recombinant protein drug manufacturing.
Based on the SUREtechnology Platform™ and unique world-class expertise, Selexis SURE Cell Line Development™ Services significantly reduce the time, effort, and costs that are associated with the development of high-performance mammalian cell lines for therapeutic protein production (e.g., development of monoclonal antibodies, bi-specific monoclonal antibodies, growth factors, and enzymes).
The development of high-yield production cell lines starts with the cloning of the gene of interest into SUREtech Vectors™ that bear Selexis SGE® (Selexis Genetic Elements). These optimally designed DNA expression vectors are then transfected into the fully documented Selexis SURE CHO-M Cell Line™ using the SUREfection™ procedure.
By applying single-cell clonings from the selected stable pools, Selexis identifies high-expressing clonal cell lines that are then evaluated for their growth characteristics using fed-batch cultures.